NCT02999477View on ClinicalTrials.gov

A Study Of Changes In PD-L1 Expression During Preoperative Treatment With Nab-Paclitaxel And Pembrolizumab In Hormone Receptor-Positive Breast Cancer

PHASE1Active, not recruitingINTERVENTIONAL
Enrollment

32

Participants

Timeline

Start Date

February 23, 2017

Primary Completion Date

November 20, 2022

Study Completion Date

January 31, 2026

Conditions
Breast Cancer
Interventions
DRUG

Pembrolizumab

Pembrolizumab will be administered in clinic every three weeks.

DRUG

Nab-Paclitaxel

Nab-Paclitaxel will be administered in clinic every week.

PROCEDURE

Biopsy

Biopsies for research purposes will be performed at three separate timepoints during treatment.

Trial Locations (1)

02215

Dana-Farber Cancer Institute, Boston

All Listed Sponsors
collaborator

Merck Sharp & Dohme LLC

INDUSTRY

lead

Adrienne G. Waks

OTHER